Background: Analyses of stored blood from the Outcomes Reduction with an Initial Glargine Intervention (ORIGIN) trial identified biomarkers that supplemented clinical risk factors for cardiovascular (CV) events or death. Their performance in participants with diabetes in the Heart Outcomes Prevention Evaluation (HOPE) study and the incremental value of adding high-sensitivity assays of serum troponin I (hsTnI) in the ORIGIN study were assessed.
T he clinical assessment of any patient with diabetes yields a personalized patient profile based on the history, physical, imaging, and laboratory tests that facilitates estimation of the risk of future health problems. The addition of validated new biologic markers to this profile can refine this individual risk evaluation, and the availability of multiplex methods to simultaneously assess levels of many circulating laboratory biomarkers in one sample, may facilitate identification of new risk factors.
Such an approach was followed using stored blood from the Outcomes Reduction with an Initial Glargine Intervention (ORIGIN) trial. Statistical analyses of 237 serum biomarkers in 8401 ORIGIN participants identified sets of biomarkers that independently predicted incident cardiovascular (CV) outcomes after accounting for routinely measured clinical risk factors. Specifically, these analyses identified 10 biomarkers for the composite outcome of nonfatal myocardial infarction, nonfatal stroke, or CV deaths; 9 biomarkers for an expanded composite that also included heart failure, hospitalization, or revascularization; and 15 biomarkers for death from any cause (1) . These sets of biomarkers were validated within the ORIGIN cohort using bootstrapping techniques. We have now further assessed the performance of the set of biomarkers that predicted the CV composite outcome using stored blood from an independent cohort of participants with diabetes who were followed in the Heart Outcomes Prevention Evaluation (HOPE) Trial (2) .
High-sensitivity assays of serum troponin I (hsTnI) are established diagnostic tests for acute myocardial infarction. They are also emerging as important prognostic factors for future CV outcomes (3) . As the multiplex panel that was initially used to assay the ORIGIN samples did not include troponin, we used a commercially available assay to measure hsTnI levels in stored blood from the 8401 ORIGIN participants in the ORIGIN biomarker study. We then assessed the discriminative properties of these levels, either alone or when added to the previously identified ORIGIN biomarkers using the ORIGIN cohort.
Materials and Methods
The ORIGIN trial followed 12,537 people with dysglycemia for a median of 6.2 years for the occurrence of CV outcomes (4, 5) . As previously published, 1 mL stored serum from a subset of 8401 participants was transported to and assayed for a set of biomarkers by Myriad RBM (Austin, TX). Biomarker levels were measured using a customized, extended version of the company's Human Discovery Multi-Analyte Profile 250 + panel on the LUMINEX 100/200 platform, which comprised biomarkers related to the pathophysiology of CV disease, diabetes, and other comorbidities. All assays were done blindly, without knowledge of any clinical information regarding the participants (1). All participants provided written informed consent, and a subset consented to analyses of their stored blood.
Identification of an external validation cohort for the predictive ORIGIN biomarkers
The HOPE trial assessed the effect of ramipril vs placebo and of vitamin E vs placebo on CV outcomes using a randomized double-blind placebo-controlled factorial design (2, 6) . Participants with a history of diabetes, with no missing baseline data pertaining to CV risk factors, who consented to the storage of blood, and for whom an aliquot of frozen baseline serum (280°C) was available, were eligible for this case-cohort analysis (7). There were 648 eligible individuals, of whom 77 (i.e., cases) developed the CV composite outcome of nonfatal myocardial infarction, nonfatal stroke, or CV death during follow-up. Sample size calculations suggested a sample of 350 participants would provide .80% power to detect a 20% or higher difference in C statistic from a baseline level of 0.6 (8) . The case-cohort was therefore constructed by randomly selecting 308 eligible participants (which included 35 of the 77 cases) and supplementing the sample with the remaining 42 participants who developed the composite outcome. The aliquots from these participants were sent to Myriad RBM for blinded analyses of the 10 biomarkers previously identified as independent predictors of the CV composite outcome in the ORIGIN trial, and the biomarker level data were sent to the Population Health Research Institute for statistical analyses.
Measurement of serum troponin in the ORIGIN cohort
A separate aliquot of serum from the 8401 participants was thawed and assayed for troponin I by a chemiluminescent microparticle immunoassay using the Architect Stat highsensitivity troponin I assay on the Abbott Architect System (Longford, Ireland). This assay has a mean interassay precision of 4.4%.
Statistical analysis

Standardization of the biomarker levels
Before analyzing the performance of the 10 ORIGIN biomarkers for the CV composite outcome in the HOPE cohort, those biomarkers that were log transformed prior to analysis in the ORIGIN cohort were similarly transformed, and all continuous variables were standardized. As was done for the other ORIGIN biomarkers, hsTnI levels were scrutinized and levels that were more or less than 4 standard deviations from the mean were assigned the level of the respective fourth standard deviation. The results were then natural logarithm transformed and standardized.
Independent validation of the ORIGIN biomarker panel in the HOPE study cohort
The previously published regression coefficients of the biomarkers identified using the ORIGIN samples (1) , and the levels of these biomarkers that were measured in stored blood from the 350 HOPE participants were used to calculate the C statistics and net reclassification improvement (NRI) for the CV composite outcome in the HOPE participants. Analyses accounted for the clinical risk factors that were included in the previously published ORIGIN analyses (1), based on the validated INTERHEART risk score (9), as follows: sex; older age (males $55 or females $65 years); prior CV event; prior diabetes; prior hypertension; current smoking; and a clinical history or laboratory evidence of micro-or macro-albuminuria. The ORIGIN analysis also included the baseline low-density lipoprotein/high-density lipoprotein (HDL) cholesterol ratio as a clinical variable. However, baseline levels of these lipoproteins were not collected in the HOPE study; instead investigators recorded whether there was a history of a low HDL level. Two different ORIGIN models were therefore applied to the HOPE data. One of these excluded the lipid term from the clinical variables, and the other replaced the low-density lipoprotein/HDL ratio with a history of a low HDL as a categorical variable.
Effect of the high-sensitivity troponin I on performance of the ORIGIN biomarker panel
Three analyses were conducted for each of the three outcomes described previously to determine whether adding the hsTnI level to the previously identified biomarkers improved the ability to predict these outcomes. All analyses accounted for the same INTERHEART clinical CV risk factors that were previously used to identify the biomarkers (9) . For the first set of analyses, the hsTnI level was added to the clinical risk factors to assess the independent effect of hsTnI alone. For the second set of analyses, the hsTnI level was added to the previously reported ORIGIN model for each outcome. Cox regression models that used the previously reported clinical and biomarker variables along with their respective b coefficients (1) were used to estimate the coefficient for hsTnI for each outcome. These models assessed the incremental effect of adding hsTnI levels to the previous model. The third set of analyses evaluated hsTnI and the other 237 biomarker levels simultaneously by using the previously reported clinical and biomarker variables but allowing the Cox regression program to estimate new coefficients for all of the variables.
The strength and direction of the relationships between biomarkers and outcomes (derived from the Cox models) were expressed as hazard ratios [95% confidence interval (CI)]. The proportional hazards assumption was tested using Schoenfeld's global test at a P value of 0.05, and interaction terms of time with each identified nonproportional independent variable were added to the models. C statistics with 95% CI were calculated for each model. For models containing biomarkers that interacted with time, the hazard ratios at 5 years were estimated. Models were compared using the category-based NRI after classifying people into four categories of risk based on the predicted probabilities of developing the outcomes of 0.05, 0.10, and 0.20. This measure reflects the degree to which one model better identifies people who did and did not develop an outcome compared with an alternative model (10-13). The probability cutoffs defining the four categories of risk were identical to those used to initially show that addition of up to 15 biomarkers to clinical risk factors better identifies individuals who will and will not develop CV events vs models with clinical risk factors alone (1) .
All statistical analyses were done using SAS Version 9.4 for UNIX (SAS Institute, Cary, NC).
Results
Validation of the ORIGIN biomarkers in HOPE study participants
The clinical characteristics of the 350 HOPE study participants who had diabetes at baseline and whose stored blood samples were assayed for this analysis (mean age 65.2 years; 35% women) are noted in Supplemental Table 1 . Using the mathematical model that was derived from the ORIGIN data, addition of the levels of the 10 ORIGIN biomarkers to the levels of the basic clinical risk factors increased the ability to predict the occurrence of the CV composite outcome. Thus, for the HOPE model that excluded lipid status from the clinical risk factors, the C statistics increased from 0.63 (95% CI, 0.57, 0.69) for the clinical risk factors alone to 0.67 (95% CI, 0.61, 0.73) for the full model, and the NRI was 0.14 (95% CI, 0.01, 0.28). Similar findings were noted for the model that included lipid status as a clinical risk factor (Supplemental Table 2 ). Calibration plots for these two models showing the proportion of outcomes that occurred within each tenth of predicted risk (Fig. 1) indicate that the models (with slopes of 0.69 and 0.64) somewhat overestimated the actual risk. Exclusion of clinical risk factors from these models reduced their calibration (data not shown). 
Discriminative value of adding troponin levels to the ORIGIN biomarkers
Complete baseline data and sufficient serum were available to analyze high-sensitivity troponin I levels in 8215 ORIGIN participants. This population comprised 2792 (34.0%) women of mean age (standard deviation) 63.7 (7.9) years, and 4878 (59.4%) reported a prior CV event. These participants experienced 1366 (16.6%) CV composite outcomes, 2374 (28.9%) expanded composite outcomes, and 1303 (15.9%) deaths during follow-up. The median (interquartile range) baseline hsTnI level was 4.6 (3.0 to 8.0) pg/mL.
After adjustment for the basic clinical risk factors alone, baseline levels of hsTnI were independent predictors of the CV composite outcome, the expanded composite outcome, and mortality, with significant hazard ratios per 1 standard deviation higher transformed value (equivalent to an increase in hsTnI levels of 2.59 pg/mL) varying from 1.34 to 1.40 (Tables 1-3 , column 1). This relationship persisted but was attenuated after accounting for the previously established ORIGIN biomarkers plus clinical risk factors. Thus, when hsTnI levels were added to the previously reported model comprising the clinical risk factors, identified ORIGIN biomarkers, and their respective b coefficients, the hazard ratio for hsTnI varied from 1.10 to 1.21 with respective CI all exceeding 1 (Tables 1-3, column 2). When hsTnI levels were included in a new Cox model that simultaneously estimated the b coefficients for the clinical risk factors, previously reported 237 ORIGIN biomarkers, and hsTnI levels, similar hazard ratios of 1.12 to 1.25 were estimated for the hsTnI biomarker with CI all exceeding 1 (Tables 1-3, column 3) . Notably, all of the previously identified biomarkers remained statistically significant predictors of the various CV outcomes after inclusion of hsTnI levels (Tables 1-3, column 3) .
When added to the clinical risk factors, the C statistics of models restricted to the clinical risk factors and serum hsTnI alone range from 0.68 to 0.69 and were clearly higher than the C statistics of models (i.e., 0.64 for all three outcomes) containing just the clinical risk factors. The addition of hsTnI levels to the previously reported biomarker models shown in column 2 of Tables 1-3 did not improve its ability to correctly classify cases (NRI ;0 for all outcomes; Table 4 ). Conversely, the new models summarized in column 3 of Tables 1-3 that included the clinical risk factors, hsTnI, and the previously identified biomarkers were better able to correctly classify cases for all three outcomes than models that just included the clinical risk factors and hsTnI levels, with NRIs ranging from 0.12 to 0.33 (Table 4) .
Interaction of troponin levels with time
The relationship between hsTnI levels and each of the three outcomes assessed varied with follow-up time regardless of whether troponin was assessed alone or in concert with the other biomarkers. In response to this hsTnI-time interaction, all of the models described previously and in Tables 1-3 were estimated using the Hazard ratios accounting for 10 previously identified biomarkers are expressed per 1 standard deviation change in biomarker level.
Abbreviations: HR, hazard ratio; N/A, not applicable; NT-proBNP, N-terminal pro-B type natriuretic peptide. a The hazard ratio for troponin was estimated after accounting for the clinical risk factors.
b The hazard ratio for troponin was estimated by adding its levels to a model that uses the coefficients derived from a model based on the clinical risk factors and 10 previously identified biomarkers. c The hazard ratio for troponin was estimated by allowing the model to estimate new hazards for the clinical risk factors and all biomarkers.
d As the relationship between these variables and death varied by duration of follow-up (i.e., there was an interaction with time)-the hazard ratio for 5 years of follow-up is shown.
relationship between hsTnI levels and outcomes during 5 years of follow-up. When assessed during followup periods ranging from 1 to 5 years (Supplemental Table 3 ), the relationship between hsTnI and each of the CV outcomes was strongest in the first year and then decreased with time.
Discussion
These analyses show that a predictive model for the CV composite that comprised 8 clinical risk factors plus 10 serum biomarkers and that was derived using data from the ORIGIN trial also discriminated between people who did and did not develop this outcome in HOPE trial participants with diabetes. The robustness of the model is highlighted by the fact that it predicted CV outcomes in HOPE trial participants who differed from the ORIGIN trial cohort in several ways (Supplemental Table 1 ) and who participated in a trial that started .10 years earlier. These differences, in addition to the longer sample storage time that may have affected the measurements, may explain the smaller change in C statistic and NRI in the HOPE vs ORIGIN participants and the modest mismatch between the predicted and observed risks noted in Fig. 1 . Cardiac troponin I as well as cardiac troponin T are both sensitive and specific indicators of myocardial injury that are commonly used to diagnose acute coronary syndromes (14) . Several analyses have shown that hsTnI levels are also prognostic tests for incident CV events and death in people without acute cardiac injury (3, 15-17 ).
These observations were confirmed by the current finding that a 1 standard deviation higher hsTnI significantly increased the risk of the CV composite, the expanded composite, and death by 40%, 34%, and 36%, respectively, after accounting for clinical risk factors. Furthermore, hsTnI levels remained independent (albeit attenuated) determinants of these three outcomes in models that also included the ORIGIN biomarkers for these outcomes noted in Tables 1-3 . This suggests that troponin I elevation may reflect CV processes that are not captured by the other identified and assessed biomarkers listed in these tables, including N-terminal pro-B type natriuretic peptide, growth differentiation factor-15, angiopoietin-2, and others. These processes may include subclinical degrees of ventricular dysfunction, cardiac injury, remodeling, inflammation, or oxidative stress that put the patient at risk for future CV outcomes or death.
These analyses assessed the incremental predictive value of the serum hsTnI level when added to the ORIGIN biomarkers in two ways. Adding the hsTnI level to the previously validated ORIGIN model that includes the clinical risk factors, specific biomarkers, and their respective effect sizes (i.e., b coefficients) did not add any discriminative ability based on unchanged C statistics and NRI (Table 4) . Conversely, re-estimating the b coefficients based on the clinical risk factors, hsTnI levels, and previous biomarkers yielded models that very modestly increased the discriminative ability of the ORIGIN model for the three outcomes (Table 4) . Thus, although hsTnI is an independent risk factor for Hazard ratios accounting for nine previously identified biomarkers are expressed per 1 standard deviation change in biomarker level.
Abbreviations: HR, hazard ratio; IGF, insulin-like growth factor; N/A, not applicable; NT-proBNP, N-terminal pro-B type natriuretic peptide. a The hazard ratio for troponin was estimated after accounting for the clinical risk factors.
b The hazard ratio for troponin was estimated by adding its levels to a model that uses the coefficients derived from a model based on the clinical risk factors and nine previously identified biomarkers. c The hazard ratio for troponin was estimated by allowing the model to estimate new hazards for the clinical risk factors and all biomarkers.
d As the relationship between these variables and death varied by duration of follow-up (i.e., there was an interaction with time)-the hazard ratio for CV outcomes, most of its discriminative information for these dysglycemic ORIGIN participants is encoded in the other, previously identified biochemical risk factors (1) . These troponin analyses are limited by the fact that they have not been replicated in an independent cohort and that the ORIGIN cohort was only followed for a median of 6.2 years. Nevertheless, the fact that they are based on .1400 incident outcomes that were prospectively collected and adjudicated, the consequent narrow CI around the estimated effect sizes, and the consistency or the results across outcomes are clear strengths.
Taken together, the analyses using HOPE trial participants, as well as the hsTnI analyses using ORIGIN data, support the discriminative value of the ORIGIN biomarker model. They also suggest that, although hsTnI levels are not required to distinguish between dysglycemic people who will and will not develop a CV event, they may provide further insight into the pathophysiology of CV disease. Further assessment of this model may extend its utility to different populations. All of the models include the eight clinical risk factors. Columns 1, 2, and 3 refer to the columns in Tables 1-3 . a In these previously published analyses (1), the net reclassification indices assessed the incremental effect of adding the ORIGIN biomarkers to the clinical risk factors. Hazard ratios accounting for 15 previously identified biomarkers are expressed per 1 standard deviation change in biomarker level.
b The hazard ratio for troponin was estimated by adding its levels to a model that uses the coefficients derived from a model based on the clinical risk factors and 15 previously identified biomarkers. c The hazard ratio for troponin was estimated by allowing the model to estimate new hazards for the clinical risk factors and all biomarkers.
